NDA 212327 · Bristol-Myers
Inrebic
Fedratinib Hydrochloride · Oral
NovelPriority reviewOrphanLast checked: Nov 21, 2026Latest source record: Jul 20, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2019
Aug 16, 2019
Approved uses
1
Original approval plus efficacy supplements
Registered trials
30
3 Phase 3, 3 recruiting
FAERS reports
1,349
687 serious, 191 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: ENCEPHALOPATHY INCLUDING WERNICKE'S Serious and fatal encephalopathy, including Wernicke's, has occurred in patients treated with INREBIC. Wernicke's encephalopathy is a neurologic emergency. Assess thiamine levels in all patients prior to starting INREBIC. Do not start INREBIC in patients with thiamine deficiency; replete thiamine prior to treatment initiation. While on treatment all patients should receive prophylaxis with daily oral thiamine and should have thiamine levels assessed as clinically indicated. If encephalopathy is suspected, immediately discontinue INREBIC and initiate parenteral thiamine. Monitor until symptoms resolve or improve and thiamine levels normalize [see Dosage and Administration (2.6) , Warnings and Precautions (5.1) and Adverse Reactions (6.1) ] . WARNING: ENCEPHALOPATHY INCLUDING WERNICKE'S See full prescribing information for complete boxed...
What it is approved for
From the label in effect Jul 20, 2026.
INREBIC ® is indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF). INREBIC is a kinase inhibitor indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF) ( 1 ).
Mechanism: Fedratinib is an oral kinase inhibitor with activity against wild type and mutationally activated Janus Associated Kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3). Fedratinib is a JAK2-selective inhibitor with higher inhibitory activity for JAK2 over family members JAK1, JAK3 and TYK2. Abnormal activation of JAK2 is associated with myeloproliferative neoplasms (MPNs), including myelofibrosis and polycythemia vera. In cell models expressing mutationally active JAK2 V617F or FLT3 ITD , fedratinib reduced phosphorylation of signal transducer and activator of transcription (STAT3/5)...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 16, 2019 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelLetterReview
1 products under this application
- INREBIC · FEDRATINIB HYDROCHLORIDE EQ 100MG BASE · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Fedratinib" as an intervention, any sponsor and status, largest first.
- Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With MyelofibrosisPivotal-lookingTerminated
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT01437787 · 289 participants · Start Dec 31, 2011 · Primary completion Jun 30, 2014
Drug: SAR302503; Placebo · For: Hematopoietic Neoplasm
Sites: Scottsdale, Arizona; La Jolla, California; Los Angeles, California · 101 sites in all
- A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)Pivotal-lookingActive, not recruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT04817007 · 216 participants (planned) · Start Mar 22, 2021 · Primary completion Aug 31, 2028
Drug: BMS-986158; Ruxolitinib and 1 more · For: Myelofibrosis
Sites: Newport Beach, California; Lake Mary, Florida; New Orleans, Louisiana · 49 sites in all
CelgeneBristol Myers Squibb (BMY)
NCT03952039 · 202 participants · Start Sep 9, 2019 · Primary completion Dec 15, 2022
Drug: FEDRATINIB; Best Available Therapy (BAT) · For: Primary Myelofibrosis; Post-Polycythemia Vera; Myelofibrosis
Sites: Darlinghurst, Australia; Adelaide, Australia; Box Hill, Australia · 107 sites in all
- A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated MyelofibrosisPivotal-lookingActive, not recruiting
Karyopharm Therapeutics IncIndustry
NCT04562870 · 112 participants (planned) · Start Mar 17, 2021 · Primary completion Sep 2026
Drug: Selinexor · For: Myelofibrosis
Sites: Pasadena, California; Aurora, Colorado; Niles, Illinois · 21 sites in all
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT01523171 · 97 participants · Start Apr 30, 2012 · Primary completion Apr 30, 2014
Drug: SAR302503 · For: Hematopoietic Neoplasm
Sites: Phoenix, Arizona; San Francisco, California; Atlanta, Georgia · 42 sites in all
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT01420783 · 81 participants · Start Oct 2011 · Primary completion Nov 2012
Drug: SAR302503 · For: Hematopoietic Neoplasm
Sites: Scottsdale, Arizona; La Jolla, California; Los Angeles, California · 35 sites in all
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT01836705 · 60 participants · Start May 2013 · Primary completion Nov 2013
Drug: SAR302503 (TG101348); Placebo SAR302503 and 1 more · For: Neoplasm Malignant
Sites: Los Angeles, California; Augusta, Georgia; Detroit, Michigan · 10 sites in all
TargeGenIndustry
NCT00631462 · 59 participants · Start Jan 2008 · Primary completion Oct 2009
Drug: TG101348 · For: Myelofibrosis
Sites: San Diego, California; Stanford, California; Boston, Massachusetts · 6 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diarrhoea146
- death141
- nausea122
- fatigue115
- vomiting73
- constipation59
- off label use58
- haemoglobin decreased54
- asthenia52
- platelet count decreased50
- full blood count decreased45
- pruritus42
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 46 |
| 2020 | 273 |
| 2021 | 282 |
| 2022 | 246 |
| 2023 | 184 |
| 2024 | 145 |
| 2025 | 106 |
| 2026 | 63 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Inrebic (Fedratinib Dihydrochloride)
2024 spending
$44.9M
Beneficiaries
328
2,187 claims
Per beneficiary
$137,003
$216.36 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $42,006,172 |
| 2021 | $47,339,211 |
| 2022 | $52,145,209 |
| 2023 | $50,007,888 |
| 2024 | $44,937,111 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial.
Pardanani A, Harrison C, Cortes JE, et al. · JAMA Oncol 2015 · Clinical Trial, Phase III, Multicenter Study
- Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial.
Harrison CN, Mesa R, Talpaz M, et al. · Lancet Haematol 2024 · Multicenter Study, Clinical Trial, Phase III
- Updated results of the placebo-controlled, phase III JAKARTA trial of fedratinib in patients with intermediate-2 or high-risk myelofibrosis.
Pardanani A, Tefferi A, Masszi T, et al. · Br J Haematol 2021 · Clinical Trial, Phase III, Randomized Controlled Trial
- Relative bioavailability of fedratinib through various alternative oral administration methods in healthy adults.
Chen Y, Wyatt D, Attanasio M, et al. · Cancer Chemother Pharmacol 2024 · Randomized Controlled Trial, Clinical Trial, Phase I
- Momelotinib versus Continued Ruxolitinib or Best Available Therapy in JAK Inhibitor-Experienced Patients with Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-2.
Harrison CN, Vannucchi AM, Recher C, et al. · Adv Ther 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Effect of fluconazole on the pharmacokinetics of a single dose of fedratinib in healthy adults.
Chen Y, Ogasawara K, Wood-Horrall R, et al. · Cancer Chemother Pharmacol 2022 · Research Support, Non-U.S. Gov't, Clinical Trial, Phase I
Sponsor: Bristol Myers Squibb
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.